Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Up 5.2% – What’s Next?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) was up 5.2% on Friday. The company traded as high as $8.09 and last traded at $8.2150. Approximately 433,505 shares changed hands during mid-day trading, an increase of 11% from the average session volume of 389,977 shares. The stock had previously closed at $7.81.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on EPRX shares. Wall Street Zen cut Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 8th. HC Wainwright increased their target price on Eupraxia Pharmaceuticals from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 15th. Royal Bank Of Canada assumed coverage on Eupraxia Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $14.00 price target for the company. Finally, Wedbush assumed coverage on Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. They issued an “outperform” rating and a $17.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Eupraxia Pharmaceuticals Trading Up 4.4%

The company has a debt-to-equity ratio of 0.03, a current ratio of 12.25 and a quick ratio of 16.00. The stock’s 50-day moving average is $7.63 and its two-hundred day moving average is $7.25. The company has a market cap of $548.07 million, a P/E ratio of -7.68 and a beta of 1.04.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its earnings results on Tuesday, November 10th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03. As a group, equities research analysts predict that Eupraxia Pharmaceuticals Inc. will post -0.90 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of EPRX. Ingalls & Snyder LLC boosted its position in Eupraxia Pharmaceuticals by 10.2% in the third quarter. Ingalls & Snyder LLC now owns 75,450 shares of the company’s stock worth $687,000 after purchasing an additional 7,000 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Eupraxia Pharmaceuticals by 28.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock worth $133,000 after buying an additional 3,500 shares during the last quarter. AXQ Capital LP increased its stake in shares of Eupraxia Pharmaceuticals by 34.2% in the 2nd quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock worth $140,000 after purchasing an additional 5,390 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Eupraxia Pharmaceuticals in the second quarter worth about $4,037,289. Finally, Bank of America Corp DE purchased a new position in shares of Eupraxia Pharmaceuticals during the 2nd quarter valued at about $1,750,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.